Loading clinical trials...

Sugammadex Given for the Reversal of Rocuronium Induced Neuromuscular Blockade Under Sevoflurane Anesthesia in Infants | Clinical Trials | Clareo Health

COMPLETEDPHASE4

Sugammadex Given for the Reversal of Rocuronium Induced Neuromuscular Blockade Under Sevoflurane Anesthesia in Infants

Sugammadex Given for the Reversal of Deep Rocuronium Induced Neuromuscular Blockade Under Sevoflurane Anesthesia in Infants: A Retrospective Study

NCT02708056•Baskent University

View on ClinicalTrials.gov

Summary

The objective of this study is to evaluate the efficacy and safety of sugammadex in reversing profound neuromuscular block induced by rocuronium in infant patients

Eligibility

Age

0 - 1 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients between the ages of 1-12 month,
•ASA physical status 1-3 who underwent elective brain cancer surgery during general anesthesia were included in the study

Exclusion Criteria

•younger than 1month or older than 12 months.
•hepatic or renal failure
•A history of allergy to study medication

Key Dates

Start Date

January 1, 2015

Primary Completion Date

February 1, 2016

Completion Date

February 1, 2016

Last Updated

March 15, 2016

Enrollment

ACTUAL participants

Conditions

Brain Cancer

Interventions

Sugammadex

DRUG

Diagnostic Performance of Fluorescein as an Intraoperative Brain Tumor Biomarker

NCT02691923

Brain Cancer

View study

RECRUITINGPHASE1/PHASE2

Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM

NCT03213002

Glioblastoma Multiforme (GBM)Glioblastoma+7 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 15, 2016Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Sugammadex Given for the Reversal of Rocuronium Induced Neuromuscular Blockade Under Sevoflurane Anesthesia in Infants

Inclusion Criteria

Exclusion Criteria

Diagnostic Performance of Fluorescein as an Intraoperative Brain Tumor Biomarker

Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM

Record Voxel Rate Nonlinear Optical Microscope to Unravel Brain Connectome and Signaling

Wearable Devices and Biomarkers Project (Healthiomics)

Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

A Study to Evaluate the Safety and Efficacy of Intracranial Venous Blood Sampling for Liquid Biopsy in the Diagnosis of Brain Cancers